ALX Oncology (ALXO) vs Codexis (CDXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
ALX Oncology (ALXO) has outperformed Codexis (CDXS) over the past year, losing 40.1% versus a loss of 48.7%. Over five years, CDXS leads with a -95.2% price change compared with -98.0% for ALXO. ALX Oncology is the larger company by market cap ($170.8 million vs $150.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALXO | CDXS |
|---|---|---|
| Share price | $1.24 | $1.38 |
| Market cap | $170.77M | $150.57M |
| 1-day change | +4.68% | +1.10% |
| YTD return | +4.42% | -16.56% |
| 1-year return | -40.10% | -48.68% |
| 5-year return | -98.00% | -95.20% |
| EPS (TTM) | $-1.13 | $-0.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.66 | $2.98 |
| 52-week low | $1.05 | $0.96 |
| Distance from 52-week high | -53.57% | -53.86% |
| Analyst consensus | none | buy |
| Avg. price target upside | +272.47% | +346.55% |
| Average volume | 1.04M | 1.12M |
| Shares outstanding | 138.28M | 109.51M |
| Employees | 48 | 146 |
| Sector | Health Care | Industrials |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- The two companies sit in different sectors: ALX Oncology in Health Care and Codexis in Industrials.
About ALX Oncology
ALXO stock →ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About Codexis
CDXS stock →Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China.
Industrials · Major Chemicals · 146 employees
ALXO vs CDXS FAQ
Which is bigger, ALX Oncology or Codexis?
ALX Oncology (ALXO) is larger, with a market capitalization of $170.77M compared with $150.57M for Codexis (CDXS).
Which stock has performed better over the past year, ALXO or CDXS?
ALXO returned -40.10% over the past 12 months, compared with -48.68% for CDXS (price return, excluding dividends). Past performance does not predict future results.
Are ALX Oncology and Codexis in the same industry?
No. ALX Oncology is in the Health Care sector, while Codexis is in Industrials.